StreetInsider.com News Articles

Form 4 Lyell Immunopharma, Inc. For: Oct 12 Filed by: Aguirre Jarrad Mattieu

Tue, 13 Oct 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20261013/27181965.html

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

Mon, 14 Sep 2026 07:00:00 -0400

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026, in New York with a fireside chat scheduled for 2:00 pm Eastern Time.

A live webcast of the fireside chat can be accessed through the Investors section of the Company's website at www.lyell.com. A replay of the

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

Mon, 14 Sep 2026 07:00:00 -0400

A live webcast of the fireside chat can be accessed through the Investors section of the Company's website at www.lyell.com. A replay of the

H.C. Wainwright Reiterates Buy Rating on Lyell Immunopharma (LYEL)

Fri, 11 Sep 2026 07:00:13 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $45.00 price target on Lyell Immunopharma (NASDAQ: LYEL).

The analyst commented: "Lyell announced completion of LYL273’s transfer to LyFE following FDA review of the improved manufacturing process and updated analytical methods. Additional Phase 1/2 data in 3L+ relapsed/refractory metastatic colorectal cancer (r/r mCRC) and the end-of-Phase 1 meeting are now expected in 2027 vs. 2H26 previously. Patients continue to receive LyFE-manufactured product, and additional sites are being activated for expansion. We view the transfer as an operational step toward larger-scale development, bringing manufacturing, dose selection, and safety optimization together ahead

Form 4 Lyell Immunopharma, Inc. For: Sep 10 Filed by: Shook David

Thu, 10 Sep 2026 19:38:00 -0400

si-local-file:///var/storage/secattach/20260910/27049755.html

Form 4 Lyell Immunopharma, Inc. For: Sep 10 Filed by: Aguirre Jarrad Mattieu

Thu, 10 Sep 2026 19:32:00 -0400

si-local-file:///var/storage/secattach/20260910/27049745.html

Form 3 Lyell Immunopharma, Inc. For: Aug 31 Filed by: Aguirre Jarrad Mattieu

Thu, 10 Sep 2026 19:30:00 -0400

si-local-file:///var/storage/secattach/20260910/27049741.html

Form 8-K Lyell Immunopharma, Inc. For: Sep 10

Thu, 10 Sep 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260910/27048559.html

Lyell shifts LYL273 trial timeline, eyes 2027 FDA meeting

Thu, 10 Sep 2026 16:05:37 -0400

Lyell Immunopharma (Nasdaq: LYEL) announced the completion of a manufacturing technology transfer for its LYL273 cancer therapy candidate to its LyFE Manufacturing Center in Bothell, Washington, following a review by the U.S. Food and Drug Administration.

The transfer involves an updated manufacturing process and revised analytical methods intended to improve manufacturing performance and increase production capacity at the facility. The company said it is continuing to dose patients in its Phase 1/2 clinical trial using the new process.

LYL273 is a guanylyl cyclase C-targeted CAR T-cell therapy candidate being evaluated in patients with third- or later-line relapsed or refractory metastatic colorectal cancer.

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

Thu, 10 Sep 2026 16:05:00 -0400

Technology transfer to LyFE Manufacturing Center™ completed following FDA review of improved manufacturing process and updated analytical methods
Dosing of additional patients with the new process at LyFE continues with the goal of determining the recommended Phase 2 dose and optimized safety management plan to support End-of-Phase 1 discussions with the FDA
Additional clinical data from the Phase 1/2 trial of LYL273 in patients with third- or later-line relapsed/refractory metastatic colorectal cancer and End-of-Phase 1 meeting with FDA expected in 2027

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma,

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

Thu, 10 Sep 2026 16:05:00 -0400

Technology transfer to LyFE Manufacturing Center™ completed following FDA review of improved manufacturing process and updated analytical methods
Dosing of additional patients with the new process at LyFE continues with the goal of determining the recommended Phase 2 dose and optimized safety management plan to support End-of-Phase 1 discussions with the FDA
Additional clinical data from the Phase 1/2 trial of LYL273 in patients with third- or later-line relapsed/refractory metastatic colorectal cancer and End-of-Phase 1 meeting with FDA expected in 2027

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma,

Form 4 Lyell Immunopharma, Inc. For: Aug 21 Filed by: Seely Lynn

Tue, 25 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260825/26974713.html

Form 4 Lyell Immunopharma, Inc. For: Aug 21 Filed by: Seely Lynn

Tue, 25 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260825/26974713.html

Form 4 Lyell Immunopharma, Inc. For: Aug 21 Filed by: Hill Stephen J.

Tue, 25 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260825/26974673.html

Form 4 Lyell Immunopharma, Inc. For: Aug 21 Filed by: Hill Stephen J.

Tue, 25 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260825/26974673.html

Form 4 Lyell Immunopharma, Inc. For: Aug 21 Filed by: Lee Gary K.

Tue, 25 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260825/26974612.html

Form 4 Lyell Immunopharma, Inc. For: Aug 21 Filed by: Lee Gary K.

Tue, 25 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260825/26974612.html

Form SCHEDULE 13G/A Lyell Immunopharma, Inc. Filed by: Foresite Capital Fund IV, L.P.

Fri, 14 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260814/26930099.html

Form SCHEDULE 13G/A Lyell Immunopharma, Inc. Filed by: Foresite Capital Fund IV, L.P.

Fri, 14 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260814/26930099.html

Lyell Immunopharma (LYEL) Reiterated at Market Outperform by Citizens

Fri, 14 Aug 2026 04:33:56 -0400

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $34.00 price target on Lyell Immunopharma (NASDAQ: LYEL).

The analyst commented, "We reiterate our Market Outperform rating and price target of $34 for Lyell Immunopharma (LYEL) based on a revenue and earnings multiple analysis. Recently, Lyell reported 2Q26 earnings and reiterated upcoming milestones including a data readout for the pivotal PiNACLE in 3L+ LBCL as well as updated efficacy data from LYL273 in 3L+ mCRC, both in 2H26. With two pivotal trials in LBCL underway, potential best-in-class activity in mCRC, and a cash position of $228MM, we view Lyell shares as

Form 4 Lyell Immunopharma, Inc. For: Aug 10 Filed by: Bulis Veronica Sanchez

Tue, 11 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260811/26906135.html

Form 4 Lyell Immunopharma, Inc. For: Aug 10 Filed by: Bulis Veronica Sanchez

Tue, 11 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260811/26906135.html

Form 4 Lyell Immunopharma, Inc. For: Aug 10 Filed by: Lee Gary K.

Tue, 11 Aug 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260811/26906110.html

Form 4 Lyell Immunopharma, Inc. For: Aug 10 Filed by: Lee Gary K.

Tue, 11 Aug 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260811/26906110.html

Form 4 Lyell Immunopharma, Inc. For: Aug 10 Filed by: Hill Stephen J.

Tue, 11 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260811/26906061.html